uniQure Reports Q3 Results with EPS Beat and Revenue Growth Amid Cash Runway Extension
uniQure (QURE) reported third-quarter financial results featuring a GAAP earnings per share of -$0.88, slightly exceeding analyst expectations by $0.01. While revenue reached $5.2 million—representing a significant 40.5% increase year-over-year—it fell short of consensus estimates by approximately $0.85 million. The biotechnology company maintains a strong liquidity position with $768.4 million in cash, cash equivalents, and investment securities as of September 30, 2026. Management stated that current resources are expected to be sufficient to fund projected operating expenses through 2030, providing long-term stability for its clinical development programs.
Tickers: $QURE
Topics: cash runway earnings report EPS beat gene therapy revenue miss